This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: Amgen Reports Q2, GILD's CAR T Therapy Gets Approval & More
by Zacks Equity Research
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
Big Drug Stock Q2 Earnings on Jul 30: LLY, GILD, VRTX & More
by Kinjel Shah
Let us take a look at five big drug/biotech companies, GILD, LLY, VRTX, ALXN, and AZN, gearing up for their earnings release.
Coronavirus Vaccine Development Puts These Stocks in Focus
by Ritujay Ghosh
Moderna and Pfizer launches two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year.
What Lies Ahead for Healthcare ETFs in Q2 Earnings?
by Sweta Killa
The healthcare sector is expected to witness substantial earnings decline of 6.9% in the second quarter, representing the second strongest sector this earnings season.
How Hard Will Coronavirus Hit Lilly's (LLY) Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Lilly's (LLY) performance when it reports second-quarter earnings.
Markets Remain Calm But More Data and Earnings are Coming
by David Borun
Equities trend sideways as we wait for Congress and 30% of the S&P is set to report results.
Will Coronavirus Woes Impact Gilead's (GILD) Q2 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports second-quarter 2020 results.
Biotech Stock Roundup: BIIB Reports Q2, GILD Acquires Stake in Private Company & More
by Zacks Equity Research
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
Earnings Preview: Gilead Sciences (GILD) Q2 Earnings Expected to Decline
by Zacks Equity Research
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche's (RHHBY) 1H20 Sales Hit by the Coronavirus Pandemic
by Zacks Equity Research
Roche's (RHHBY) performance in first-half 2020 was unimpressive as it bears the brunt of the COVID-19 outbreak.
Gilead (GILD) to Buy 49.9% Stake in Private Cancer Drugmaker
by Zacks Equity Research
Gilead (GILD) will acquire a 49.9% stake in Tizona Therapeutics, Inc., a privately-held cancer drugmaker, for $300 million.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $78.08, moving +0.74% from the previous trading session.
Bristol-Myers' (BMY) CAR T Cell Therapy Gets EMA Validation
by Zacks Equity Research
Bristol-Myers' (BMY) MAA for its experimental candidate, liso-cel, gets validated by EMA.
Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Ceylad Gets FDA Nod to Begin Phase I Study on CAR T Candidate
by Zacks Equity Research
Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.
Equillium Gains From Positive Results on Coronavirus Drug
by Zacks Equity Research
Equillium (EQ) soars on positive results on pipeline candidate, itolizumab, for COVID-19.
FDA Aims to Fast-Track Coronavirus Vaccine: 3 Stocks in Focus
by Ritujay Ghosh
Vaccine seems to be the only hope now to counter the pandemic given that millions of new cases of coronavirus are being reported every day.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $76.68, moving +0.47% from the previous trading session.
Gilead Presents Additional Data on Coronavirus Drug Remdesivir
by Zacks Equity Research
Gilead (GILD) announces a comparative analysis of remdesivir, wherein the drug was associated with a 62% reduction in risk of mortality compared to standard of care.
PepsiCo Beats in Q2, Disney World Reopens
by Mark Vickery
If Disney World reopens without creating a new disease hot spot, this may be a go-ahead sign for other entertainment facilities in other heavily affected regions of the U.S.
Q2 Earnings Season Kicks Off
by Zacks Equity Research
Q2 Earnings Season Kicks Off
Stock Market News for Jul 13, 2020
by Zacks Equity Research
Benchmarks ended higher on Friday as investors cheered positive results from Gilead's coronavirus vaccine candidate, remdesivir's clinical trial data, overlooking spike in new cases.
June PPI Drops Unexpectedly
by Zacks Equity Research
June PPI Drops Unexpectedly.
Fate's IND Application for CAR T Cell Therapy Gets FDA Nod
by Zacks Equity Research
Fate (FATE) obtains FDA clearance for its IND application for FT819, targeting CD19+ malignancies.
June PPI Weak at -0.2%, COVID Drug Adds Promise
by Mark Vickery
June Producer Price Index headline of -0.2% was a big miss from the +0.4% consensus and the +0.4% headline for May.